Dianthus Therapeutics, Inc. (DNTH) Presents at UBS Global Biopharma Conference 2026 Transcript
Dianthus Therapeutics' legacy revenue has contracted from $2.2M in 2024Q3 to $1.2M in 2026Q3, while R&D expense has climbed to $45.6M per quarter, pushing operating losses to -$58.5M and free cash flow to -$50.7M.
Price trend, volume and key moving averages
Trailing total returns as of 11/18/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Nov 4, 2026 | -$0.81+14.2% vs -$0.94 | $1M+162.5% vs $460,928 |
Q3 2026 Aug 4, 2026 | -$0.90-6.3% vs -$0.85 | $761,000+156.1% vs $297,182 |
Q2 2026 May 5, 2026 | -$0.85+27.4% vs -$1.17 | $463,000+14.7% vs $403,615 |
Q2 2026 Mar 9, 2026 | -$1.43-45.9% vs -$0.98 | $284,000-48.6% vs $552,231 |
Dianthus Therapeutics, Inc. (DNTH) Presents at UBS Global Biopharma Conference 2026 Transcript
Dianthus Therapeutics, Inc. (NASDAQ: DNTH - Get Free Report) EVP Ryan Savitz sold 100,713 shares of the business's stock in a transaction on Monday, November 9th. The shares were sold at an average price of $90.54, for a total transaction of $9,118,555.02. Following the transaction, the executive vice president owned 29,276 shares in the company, valued
The mean of analysts' price targets for Dianthus Therapeutics, Inc. (DNTH) points to a 61.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Dianthus Therapeutics, Inc. (DNTH) came out with a quarterly loss of $0.81 per share versus the Zacks Consensus Estimate of a loss of $1. This compares to a loss of $0.97 per share a year ago.
Benchmark DNTH against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Dianthus Therapeutics, Inc. (DNTH)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $86.98 | $3.63B | -125.35 | -67.35% | -1463.83% | -3.87% | — | |
| $1.01 | $135.24M | -1.76 | — | — | -73.35% | — | |
| $33.21 | $6.85B | -13.49 | — | -7173.52% | -63.01% | — | |
| $16.39 | $2.06B | -4.69 | -4.26% | -445% | -90.04% | — | |
| $107.78 | $5.2B | 17.60 | 5.91% | 31.67% | 49.07% | 4.66% | |
| $26.88 | $3.14B | -5.06 | — | — | -117.35% | — |
Dianthus Therapeutics, Inc. (DNTH) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Dianthus Therapeutics, Inc. (DNTH) SEC filings — annual & quarterly reports (10-K, 10-Q)
Nov 4, 2026·SEC
Aug 4, 2026·SEC
Jun 12, 2026·SEC
Get notified when DNTH posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Dianthus Therapeutics, Inc. (DNTH) stock FAQ — growth, dividends, profitability & financials explained
Dianthus Therapeutics, Inc. (DNTH) reported $2.7M in revenue over the trailing twelve months. Revenue was $2.0M in fiscal year 2025.
Dianthus Therapeutics, Inc. (DNTH) revenue fell by 11.7% over the trailing twelve months, compared with the twelve months before.
No. Dianthus Therapeutics, Inc. (DNTH) reported a net loss of $39.8M over the trailing twelve months.
Dianthus Therapeutics, Inc. (DNTH) had a return on equity (ROE) of -3.9% over the trailing twelve months. A negative ROE means the company lost money over the period.
Dianthus Therapeutics, Inc. (DNTH) had negative free cash flow of $175.9M over the trailing twelve months.